http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Hana,Yoon, Jin Young,Park, Kyeong Hye,Kim, Do Young,Ahn, Sang Hoon,Han, Kwang-Hyub,Chon, Chae Yoon,Park, Jun Yong WJG Press 2012 WORLD JOURNAL OF GASTROENTEROLOGY Vol.18 No.16
<P>To evaluate long-term clinical course of Budd-Chiari syndrome (BCS) and predictive factors associated with the development of hepatocellular carcinoma (HCC) and survival.</P>
( Hana Park ),( Seung Up Kim ),( Jun Jeong Choi ),( Jun Yong Park ),( Sang Hoon Ahn ),( Kwang Hyub Han ),( Chae Yoon Chon ),( Young Nyun Park ),( Do Young Kim ) 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.4
A 63-year-old man with a history of hepatitis-B-related hepatocellular carcinoma (HCC) in the left lateral portion of the liver received repeated transcatheter arterial chemoembolization (TACE) and salvage radiotherapy. Two months after completing radiotherapy, he presented with dysphagia, epigastric pain, and a protruding abdominal mass. Computed tomography showed that the bulging mass was directly invading the adjacent stomach. Endoscopy revealed a fistula from the HCC invading the stomach. Although the size of the mass had decreased with the drainage through the fistula, and his symptoms had gradually improved, he died of cancer-related bleeding and hepatic failure. This represents a case in which an HCC invaded the stomach and caused a hepatogastric fistula after repeated TACE and salvage radiotherapy. (Korean J Hepatol 2010;16:401-404)
( Hana Park ),( Jae Hyung Jung ),( Min Kyung Jung ),( Jun Yong Park ),( Do Young Kim ),( Sang Hoon Ahn ),( Simon Weonsang Ro ),( Jeon Han Park ),( Eui-cheol Shin ),( Kwang-hyub Han ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Regulatory T cell (Treg) play an essential role in regulation of antitumor immunity. Although several studies regarding Treg in hepatocellular carcinoma (HCC) have been reported, knowledge of Treg after transarterial chemoembolization (TACE) is still unrevealed. The aim of this study was to investigate clinical impact of Treg in HCC patients who treated with TACE. Methods: We measured the frequency of peripheral blood Tregs in 23 healthy controls and 27 HCC patients undergoing TACE between 2010 and 2012 at Severance Hospital. The patients were divided into two groups according to tumor response; complete response group and incomplete response group. Results: The frequency of Treg in HCC patients was significantly higher than in healthy controls (7.52±2.62% vs. 4.99±1.4%, P<0.001). In a Treg subpopulation, the frequency of Treg (II) was significantly higher in HCC patients than in healthy controls (2.51±1.08% in HCC vs. 0.60±0.28% in healthy controls, P<0.001). In comparison of Tregs numbers at baseline and post-TACE by tumor response, the change of Treg (III) in complete response group from before to after TACE was statistically significant (63.8±42.2/mm3→53.2±31.9/mm3, P=0.050). The complete response group contained more patients with low post-TACE Treg (III) numbers, and the incomplete response group more patients with high post-TACE Treg (III) numbers, with statistical significance (70.9% vs. 29.4% in complete response group; 30.0% vs. 70.0% in incomplete response group, P=0.040). Patients with high post-TACE Treg (III) exhibited a significantly shorter time to progression than those with high post-TACE Treg (III) (3.8 months vs. 11.6 months, P=0.038). On multivariate analysis, hypoalbuminemia (HR 3.324; 95% CI (1.098-10.063), P=0.034) and high post-TACE Treg (III) (HR 3.080; 95% CI (1.091-8.696), P=0.034) were independent sig-nificant prognostic factors in terms of progression. Conclusions: High peripheral blood Treg (III) levels at 1 month after TACE were independently prognostic of poor progression-free survival.
( Soo-kyung Park ),( Chang Hwan Choi ),( Jaeyoung Chun ),( Heeyoung Lee ),( Eun Sun Kim ),( Jae Jun Park ),( Chan Hyuk Park ),( Bo-in Lee ),( Yunho Jung ),( Dong-il Park ),( Do Young Kim ),( Hana Park 대한장연구학회 2020 Intestinal Research Vol.18 No.1
The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD. (Intest Res 2020;18:18-33)
Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis
( Hana Park ),( Sung Hoon Kim ),( Yoo Mi Cho ),( Hyo Jin Ihm ),( Young Sang Oh ),( Seung Hwa Hong ),( Hee Dong Chae ),( Chung Hoon Kim ),( Byung Moon Kang ) 대한산부인과학회 2016 Obstetrics & Gynecology Science Vol.59 No.2
Objective Nuclear factor kappa-B (NF-кB) is a critical proinflammatory regulator that has been suggested to play a pivotal role in the pathogenesis and pathophysiology of endometriosis. In the present study, we aimed to evaluate whether the expression of NF-кB p65 subunit is increased in the eutopic endometrium and/or in the adenomyosis nodule of women with adenomyosis. Methods Thirty-three women with histologically confirmed adenomyosis after laparoscopic or transabdominal hysterectomy were recruited. Women with carcinoma in situ of uterine cervix without evidence of adenomyosis or endometriosis (n=32) served as controls. Formalin-fixed, paraffin-embedded archival tissues were sectioned and immunostained utilizing a monoclonal anti-human NF-кB p65 subunit antibody, and the immunoreactivity of NF-кB p65 subunit was compared between women with and without adenomyosis. Results The immunoreactivities of both the nuclear and the cytoplasmic NF-кB p65 subunit were significantly increased in the stromal cells in the eutopic endometrium as well as in the adenomyosis nodule of women with adenomyosis compared with controls, respectively. The nuclear expression of NF-кB p65 subunit was significantly higher in the glandular cells in the eutopic endometrium as well as the adenomyosis nodule of women with adenomyosis compared with controls, respectively. Conclusion The expression of NF-кB p65 is increased in the eutopic endometrium and adenomyosis nodule of women with adenomyosis, which strongly suggest that NF-кB plays a critical role in the pathogenesis and/or pathophysiology of adenomyosis.
Total synthesis of 2′,4′,6′‐trimethoxy‐3′,5′‐dimethylchalcone derivatives
Park Rae Yeon,Lee Hana,Park Kwangyong 대한화학회 2022 Bulletin of the Korean Chemical Society Vol.43 No.5
2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone (DMC), which is isolated from plants, has recently attracted much attention due to its beneficial pharmacological effects. The preparation of twelve 2′,4′,6′-trimethoxy-3′,5′- dimethylchalcone (DMDMC) derivatives, which are dimethylated-derivatives of DMC, is reported herein for the first time. Our synthetic method allowed the efficient construction of the DMDMC derivatives from phloroglucinol in 37.8%– 46.5% overall yields. This promising approach would be advantageous for the production of many different DMDMC derivatives in a short period of time.
( Hana Park ),( Ji Yeoun Kim ),( Tae Yeob Kim ),( Nae-yun Heo ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Although direct acting antivirals have been emerged in Korea, peginterferon and ribavirin is still remained as a therapeutic option for treating chronic hepatitis C. We surveyed to evaluate the adherence to KASL guideline for the management of adverse events in treating chronic hepatitis C with interferon based regimen. Methods: A nationwide survey study to hepatologists and gastroenterologists at general hospital or tertiary university hospital was conducted from June, 2014 to August, 2014. A survey was performed with questionnaire composed of 25 items regarding clinical practice and therapeutic options for adverse events of peginterferon and ribavirin. Results: Among 120 physicians surveyed, 71 eligible questionnaires returned and completed surveys. Most of the physicians (87.3%) were occupied at tertiary university hospital and mean clinical practice term was 12.1 years (1-41 years). Most physicians agreed to stop or reduce peginterferon according to KASL guidelines regarding neutropenia and thrombocytopenia (70.5%, 81.7%, respectively). However, lesser physicians of 58% agreed to stop or reduce ribavirin according to KASL guideline regarding anemia. Some physicians have answered that they choose erythropoietin or transfusion instead of handling ribavirin in the anemic condition (n=3, 4.2%). Physicians with longer clinical practice term tend to be lesser adherent to KASL guideline regarding anemia in terms of handling ribavirin. Before starting peginterferon and ribavirin, 95.8% physicians evaluated TSH and free T4 level for evaluating thyroid disease, and 77.5% monitored TSH and free T4 regularly with 2-4 month intervals as suggested in KASL guideline. Pretreatment evaluation of psychiatric problems such as depression was done in 72% physicians. However, lesser physicians performed evaluating cardiac and pulmonary diseases before starting treatment (64.8%, 66.2%, respectively). Conclusions: This is the first national survey to examine the adherence to KASL guideline for the management of adverse events in treating chronic hepatitis C with interferon based regimen.
Management of Side Effects in HCV Patients with Antiviral Agents
Hana Park(박하나) 한국간담췌외과학회 2014 한국간담췌외과학회 학술대회지 Vol.2014 No.4
The treatment of hepatitis C has dramatically improved over the past decade. Unlike any other chronic viral infection, a significant proportion of patients with chronic hepatitis C can be cured. In addition, first generation protease inhibitors (boceprevir and telaprevir) in combination with PEG-IFN/RBV are a major advancement in the treatment of both naive and treatment-experienced genotype 1 patients. Despite these advances, side effects of treatment in HCV patients with antiviral agents are common. The management of the various side effect profiles is recognized as the challenging problems. This review describes the side effects of current standard therapy of pegylated interferon/ribavirin and new generation DAAs (boceprevir and telaprevir) and proper management of the complications in HCV patients with antiviral agents.